aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

aTyr Pharma (LIFE) reports robust Q4 earnings, advances lead candidate

aTyr Pharma (LIFE) is well-positioned with a strong financial standing, a focus on innovative drug development for inflammatory diseases, and ongoing clinical trials for lead candidate efzofitimod targeting ILD and pulmonary sarcoidosis. While facing challenges in addressing analyst inquiries, the company has opportunities to advance its pipeline and leverage its financial resources for future growth.

aTyr Pharma progresses efzofitimod for ILD treatment, eyes transformative growth

aTyr Pharma's strong performance in advancing efzofitimod, solid financial position, and focus on innovation position them well for future growth and success
While facing challenges in pivotal studies and program management, the company's opportunities in pipeline expansion and disruptive drug discovery set a positive trajectory

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.

aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.

aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2020 Results - Earnings Call Transcript

C omplete s e nrollment of ATYR1923 c linical t rial in patients with COVID-19 s evere r espiratory c omplications . Topline data is expected at turn of calendar year.

aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

Peer-reviewed paper supports aTyr's antibody program .

aTyr Pharma Announces Publication in the Journal mAbs

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel titled, “Immune Modulators to Ameliorate COVID-19” as part of the ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28, 2020.

aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th

Eros

RF Industries

Although penny stocks come with an added element of risk, investing in the right stocks could set you up for massive gains in the future. Here are the best penny stocks to buy right now.

3 Penny Stocks That Are Ready to Take Off

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan

Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months.

aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Amyris

Baudax Bio

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead.
The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared first on InvestorPlace.

3 Penny Stocks That Have Triple-Digit Upside Potential

SAN DIEGO, Sept.  09, 2020  (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present at two investor conferences in September.

aTyr Pharma to Present at September Investor Conferences

SAN DIEGO, Sept.  02, 2020  (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17.

aTyr Pharma to Present at Life Sciences Investor Forum on September 17th

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2020 Results - Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q2 Loss, Misses Revenue Estimates

Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT 

aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan.

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer.

aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

 Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry.   Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses.

aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.

aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

Assurant

Avantor Inc.

Blueprint Medicines

Boston Scientific

Cigna

Fortive

Visa

Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

8 Stocks Viking Global Investors Continues to Buy

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2020 Results - Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Q1 Earnings and Revenues Surpass Estimates

Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT

News for aTyr Pharma Stock (LIFE)